ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary ... (otimproved. Twenty-four (24) subjects ha...)

ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema

Date:11/12/2008

ot improved. Twenty-four (24) subjects have been followed for greater than one year.

Four hundred and forty seven (447) acute attacks were treated in 82 subjects who had at least one attack. The primary locations of treated attacks were extremities (68); facial (48); gastrointestinal (272); genitourinary (9); and laryngeal (50). According to additional study findings, the median time to improvement was 30 minutes in the 447 attacks that occurred, and 93.4 percent of patients reported improvement in symptoms within 4 hours, regardless of how many times they had previously received Cinryze. None of the subjects in this study treated for laryngeal attacks required hospitalization or intubation, and no serious adverse reactions were considered related to Cinryze administration.

New Data Support Need to Improve Screening for HAE

Despite the potential severity of HAE-related attacks, many patients experience significant delays in receiving an accurate diagnosis of HAE, according to recent survey findings that were also presented at the ACAAI Annual Meeting.

HAE patients from the US, UK, France, Germany, and the Netherlands were invited by their local HAE organization to participate in an online, anonymous online survey. The surveys sought to determine patients' family history of HAE, observe the flow of patients through the healthcare system, and identify differences in medical care. Three hundred and thirteen (313) participants, with an average age of 37 years, completed the questionnaire.

Results from this survey were presented in an abstract entitled "Shortcomings in the diagnosis of hereditary angioedema: Are we adequately screening family members of affected patients?" These results indicated that 65 percent of patients were initially misdiagnosed, which resulted in an unnecessary surgical procedure in more than 20 percent of patients. The average time to diagnosis was 8.3 years after initial presentation of symptoms, and patients a
'/>"/>

1

GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
2. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
3. ViroPharma Announces Discontinuation of HCV-796 Development
4. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
5. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. ViroPharma to Present at the Natixis Bleichroeder Conference
7. ViroPharma to Present at Three Upcoming Healthcare Conferences
8. Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
9. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
10. Anesiva Announces Adlea ACTIVE-1 Phase 3 Clinical Results, Ceasing of Zingo Commercial Operations and Restructuring
11. Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test

Post Your Comments:

ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary ...(otimproved. Twenty-four (24) subjects ha...),Health